MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.750
-1.300 (-14.36%)
As of 1:33PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close9.050
Open8.900
Bid7.900 x 1800
Ask7.950 x 1200
Day's Range7.750 - 8.950
52 Week Range5.200 - 24.250
Volume344,185
Avg. Volume360,988
Market Cap434.072M
Beta1.31
PE Ratio (TTM)N/A
EPS (TTM)-9.011
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Melinta Therapeutics to Present at the JMP Securities Life Sciences Conference

    NEW HAVEN, Conn., June 13, 2018-- Melinta Therapeutics, Inc., a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced ...

  • PR Newswire12 days ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...

  • GlobeNewswire18 days ago

    Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that 20 presentations are planned at the American Society for Microbiology’s annual ASM Microbe 2018 meeting from June 7-11, 2018 in Atlanta, GA. In addition, Melinta will have multiple presentations on the potential of its experimental, pre-clinical pyrrolocytocines, including in the treatment of bio-threats such as Yersinia pestis (plague) and Bacillus anthracis (anthrax). Poster and oral presentations for Melinta’s commercial and clinical-stage programs follow.

  • GlobeNewswire20 days ago

    Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the underwriters of its recently announced public offering of 22,000,000 shares of its common stock have exercised in full their option purchase an additional 2,640,000 shares.

  • GlobeNewswire25 days ago

    Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

    NEW HAVEN, Conn., May 24, 2018-- Melinta Therapeutics, Inc., a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced ...

  • GlobeNewswire26 days ago

    Melinta Therapeutics Announces Pricing of Public Offering of Common Stock

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the pricing of an underwritten public offering of 22,000,000 shares of its common stock at $5.00 per share, before underwriting discounts and commissions.  The size of the offering was upsized from $75,000,000 to $110,000,000.  In addition, the underwriters have a 30-day option to purchase up to an additional 2,640,000 shares of common stock from Melinta on the same terms and conditions.

  • GlobeNewswire28 days ago

    Melinta Therapeutics Announces Proposed Offering of Common Stock

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $75,000,000. All of the shares of the common stock to be sold in the offering are to be sold by Melinta. Certain of Melinta’s principal and other shareholders and their respective affiliates and associates, as well as certain of Melinta’s directors and executive officers, have indicated an interest in purchasing shares of our common stock in the offering at the public offering price with an aggregate value of up to $50,000,000.

  • GlobeNewswirelast month

    Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the launch of a new antibiotic stewardship program designed to address the growing threat of antimicrobial resistance (AMR). The Melinta Antimicrobial Stewardship Program will further Melinta’s leadership in the fight against the global public health threat of antimicrobial resistance (AMR) by implementing comprehensive measures and metrics within the company’s commercial, manufacturing and research and development operations designed to promote the responsible and sustainable use of its current and future antibiotic portfolio.

  • GlobeNewswirelast month

    Melinta Therapeutics Reports First Quarter 2018 Financial Results

    Strong Product Sales Performance Across Entire Portfolio. Continuing to Optimize Operations to Achieve Cost Synergies. Important Achievements for Development and Discovery Efforts Including CARB-X Funding ...

  • GlobeNewswirelast month

    Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced a significant corporate presence at the upcoming Making a Difference in Infectious Diseases (MAD-ID) 2018 Annual Meeting from May 9-12, 2018 in Orlando, Florida. Melinta will be presenting 12 posters summarizing results from clinical and in vitro studies of Baxdela™ (delafloxacin), Orbactiv® (oritavancin) for injection and Vabomere™ (meropenem and vaborbactam). Detailed safety and efficacy findings from the Phase 3 PROCEED studies of Baxdela in patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) will be presented.

  • GlobeNewswirelast month

    Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has entered into a partnership with CARB-X, under which Melinta will be awarded up to $6.2 million to support the development of the company’s investigational pyrrolocytosine compounds. Under the terms of the partnership, Melinta will receive an initial award of up to $2.3 million from CARB-X, with the possibility of $3.9 million in additional awards based on the achievement of certain project milestones. The pyrrolocytosines have been designed de novo, from the ground up, in a site not previously exploited by the many successful classes of antibiotics that target the ribosome.

  • GlobeNewswire2 months ago

    Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced it intends to release its first quarter 2018 financial results on May 8, 2018, following the closing of the U.S. financial markets. Melinta will host a conference call and live webcast on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results and provide a business update. On May 8, 2018 at 4:30 p.m. ET, the live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers and using conference ID # 6689334.

  • GlobeNewswire2 months ago

    Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations

    NEW HAVEN, Conn., April 23, 2018-- Melinta Therapeutics, Inc., a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, has presented ...

  • GlobeNewswire2 months ago

    Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, presented findings at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting highlighting data for RX-P2382, an advanced lead investigational compound from the newly developed pyrrolocytosine class. Pyrrolocytosines were specifically designed by Melinta to target previously untapped binding sites on bacterial ribosomes and optimized for activity against today’s “superbugs”.

  • PR Newswire2 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...

  • GlobeNewswire2 months ago

    Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018

    NEW HAVEN, Conn., April 16, 2018-- Melinta Therapeutics, Inc., a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced ...

  • Associated Press3 months ago

    Cempra reports 4Q loss

    On a per-share basis, the Chapel Hill, North Carolina-based company said it had a loss of $1.48. The drugmaker posted revenue of $4.2 million in the period. For the year, the company reported that its ...

  • ACCESSWIRE3 months ago

    Melinta Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Melinta Therapeutics, Inc. (NASDAQ: MLNT ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at 8:30 AM Eastern ...